secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2026-08-11T11:14:05+00:00
Accession:  0001628280-26-055490
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4T Q2 2026 net loss $23.6M ($0.18/sh), cash $300.4M, cemsidomide trials on track
--------------------------------------------------------------------------------

- Q2 2026 revenue $6.6M (vs $6.5M YoY); net loss $23.6M vs $26.0M; EPS -$0.18 vs -$0.37.
- Cash, equivalents & securities $300.4M at Jun 30, 2026; funded to end of 2028.
- Phase 2 MOMENTUM enrollment on track for Q1 2027; ORR data expected H2 2027.
- Roche DAC collaboration: $20M upfront paid May 2026; new Phase 1b trial with daratumumab/carfilzomib to start H1 2027.
- EHA 2026 data: ORR 40% at 75 µg and 53% at 100 µg doses in late-line MM; 2 MRD-negative patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026055490/0001628280-26-055490-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026055490/cccc-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-055490

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer